Dr. Moses is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
37 Popple Dungeon Rd
Charlotte, VT 05445Phone+1 802-425-4594
Summary
- Dr. Moses is a full professor Emeritus at the Robert Larner College of Medicine, University of Vermont. He is the former Medical Director at Takeda Pharmaceuticals and is actively consulting for Pharma Companies as a expert in the GI space.
Doctor Moses received his M.D. medical degree from Case Western Reserve University School of Medicine where he was elected to the Alpha-Omega-Alpha honor medical society. His post-graduate training in Internal Medicine, Gastroenterology and Hepatology was at Dartmouth Medical School and the Dartmouth Hitchcock Medical Center. He is the author of many peer reviewed articles in GI Medicine and Endoscopy.
Education & Training
- MIT Sloane School of ManagementCertificate, Leadership Enterprise, 2009 - 2009
- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Gastroenterology, 1995
- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 1990 - 1993
- Case Western Reserve University School of MedicineClass of 1990
- Lake Forest CollegeB.A., with Honors, 1981
Certifications & Licensure
- VT State Medical License 1991 - 2026
- MA State Medical License 2021 - 2022
- NY State Medical License 2009 - 2021
- ABIM GI
Awards, Honors, & Recognition
- Alpha Omega Alpha AOA Ohio Chapter, 1990
- Research Award UVMMG, 2016
- Novartis Motility Award for presentation 2016
- Join now to see all
Clinical Trials
- Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis Start of enrollment: 2015 Dec 01
- A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) Start of enrollment: 2018 Feb 27
- An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis Start of enrollment: 2018 Apr 04
Publications & Presentations
PubMed
- 10 citationsInterplay of broccoli/broccoli sprout bioactives with gut microbiota in reducing inflammation in inflammatory bowel diseases.Johanna Holman, Molly Hurd, Peter L Moses, Gary M Mawe, Tao Zhang
The Journal of Nutritional Biochemistry. 2023-03-01 - 24 citationsDynamic Colonization of Microbes and Their Functions after Fecal Microbiota Transplantation for Inflammatory Bowel DiseaseNathaniel D. Chu, Jessica W. Crothers, Le T T Nguyen, Sean M. Kearney, Mark Smith
Mbio. 2021-07-20 - 72 citationsDaily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study.Jessica W. Crothers, Nathaniel D. Chu, Le Thanh Tu Nguyen, Magen Phillips, Cheryl Collins
BMC Gastroenterology. 2021-07-08
Journal Articles
- Partially covered self-expandable metal stents versus polyethylene stents for malignant biliary obstruction: A cost effectiveness analysisAN Barkum, V Adam, M Martel, K AlNaamani, PL Moses, Canadian Journal of Gastroenterology and Hepatology, 1/1/2015
- Partially covered self-expandable metal stents vs plastic stents for malinent bilary obstruction: Acost-effectiveness analysisBarkun,A, Martel, M, Alnaamani and Moses, PL, Can Journal of Gastroenter and Hepatology, 1/1/2015
- Randomized trial in malignant biliary obstruction: Plastic vs partially covered metal stentsMoses, PL, Martel, M, Alnaamani, A, Stuart, G, Adam, V, Kowalski, T, Mitty, R, Barkun,A, Branch, MS, World Journal of Gastroenterology, 1/1/2013
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Cost effectiveness of partially covered self-expandable metal stents vs. Polyethylene stents for malignant biliary obstruction.Moses PL, Annual Scientific Meeting of the AGA, Chicago, IL, 1/1/2013
- Mucosal serotonin signaling is altered in chronic constipation.Costedio MM, Moses PL, Brooks E, Glass L, Wood M, Ganguly EK, Coates MD, Speer C, Hyman NH, Mawe GM, Annual AGA Meeting, 1/1/2008
- Altered Intestinal Serotonin Signaling in Opiate-Induced Constipation.Coates MD, Costedio MM, Ganguly EK, Callahan MJ, Mawe GM, Moses PL, American Journal of Gastroenterology; Annual Scientific Meeting of the American College of Gastroenterology, 1/1/2006
- Join now to see all
Lectures
- FMT in Ulcerative colitis MIT/Finch/OpenBiomeCambridge, MA - 1/1/2017
- Serotonin signaling in the human gut.Cambridge, MA - 1/1/2017
- Manipulating the Gut Microbiota: Therapeutic Potential for Treatment of C. Difficile and Other GI Disorders.Nashua, NH - 1/1/2017
- Join now to see all
Other
- Discoveries and Breakthroughs Inside Science.Moses PL, Syndicated TV Broadcast: ABC
Los Angeles, CA - 1/11/2004 - Atypical Serotonin Concentrations found in Patients with IBS and Ulcerative Colitis – First Molecular Marker for Functional Bowel Disorders IdentifiedMoses PL, Gastroenterology and Endoscopy News
1/1/2004 - Featured Article: While Poorly Understood, IBS is uniquely suited to DM Intervention.Moses PL, Managed Healthcare Executive Shelley Rose
1/1/2004 - Join now to see all
Committees
- Member, UVM Professional Standards Committee
Professional Memberships
- Fellow
- Fellow
External Links
- Research gatehttps://www.researchgate.net/profile/Peter_Moses
- Linkedinhttps://www.linkedin.com/in/peter-moses-2b3803b/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: